Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1101
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravitreal
01
Overview
QL1101 is a biosimilar of bevacizumab developed by Qilu Pharmaceutical. It is a recombinant humanized monoclonal antibody that targets and inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis—the formation of new blood vessels—which is critical for tumor growth and metastasis. The drug has demonstrated pharmacokinetic equivalence, efficacy, and safety comparable to the reference product Avastin (bevacizumab) in clinical trials involving patients with non-small cell lung cancer (NSCLC) and metastatic colorectal cancer. QL1101 was approved in China in December 2019 under the brand name Ankeda/Ankada for advanced or metastatic NSCLC and metastatic colorectal cancer[1][3][4][5][6].
- Brand names
- AnkedaAnkada
- Other names
- bevacizumab biosimilarrecombinant anti-VEGF humanized monoclonal antibody injection
02
Targets
Beyond the preview
Go deeper on QL1101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1101.